Compare · ASLE vs EW
ASLE vs EW
Side-by-side comparison of AerSale Corporation (ASLE) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ASLE operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $52.38B, about 195.6x ASLE ($267.7M).
- ASLE has been more active in the news (10 items in the past 4 weeks vs 3 for EW).
- EW has more recent analyst coverage (25 ratings vs 6 for ASLE).
- Company
- AerSale Corporation
- Edwards Lifesciences Corporation
- Price
- $5.62+0.18%
- $90.83+0.31%
- Market cap
- $267.7M
- $52.38B
- 1M return
- -
- +9.41%
- 1Y return
- -
- +11.74%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 10
- 3
- Recent ratings
- 6
- 25
AerSale Corporation
AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as storage and disassembly services. This segment also provides aircraft modifications, cargo/tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ASLE
- Officer Finazzo Nicolas was granted 259,965 shares, increasing direct ownership by 60% to 694,434 units (SEC Form 4)
- Officer Garmendia Martin was granted 29,246 shares, increasing direct ownership by 16% to 212,623 units (SEC Form 4)
- Officer Hechenberger Paul Andrew was granted 29,246 shares, increasing direct ownership by 201% to 43,827 units (SEC Form 4)
- Officer Jones Gary Edmund was granted 32,495 shares, increasing direct ownership by 20% to 194,900 units (SEC Form 4)
- Chief Information Officer Pizzi Enrique was granted 15,164 shares, increasing direct ownership by 19% to 96,388 units (SEC Form 4)
- Officer Tschirhart Benjamin Thomas was granted 15,164 shares, increasing direct ownership by 47% to 47,651 units (SEC Form 4)
- Officer Wright Frederick Craig was granted 17,331 shares, increasing direct ownership by 8% to 230,862 units (SEC Form 4)
- SEC Form 10-Q filed by AerSale Corporation
- AerSale Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AerSale Reports Second Quarter 2026 Results
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results